Markets:

Overview

News

Currencies

International

Treasuries

AbbVie (NY:ABBV)

226.08 -2.63 (-1.15%)

Official Closing Price Updated: 7:00 PM EST, Dec 5, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9

...

90 91 Next >

Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79% ↗

August 08, 2025

Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales outlook after Q2 beat.

Via Benzinga

Trump Threatens Pharma With Potential 250% Tariffs In 18 Months: 'We Want Pharmaceuticals Made In Our Country' ↗

August 06, 2025

President Donald Trump has indicated the possibility of imposing tariffs on imported pharmaceuticals that could rise up to 250%, indicating the highest rate he has proposed so far.

Via Benzinga

Topics Government World Trade

1 S&P 500 Stock with Competitive Advantages and 2 We Brush Off

August 05, 2025

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth,...

Via StockStory

Topics Stocks

AbbVie (ABBV) Q2 2025 Earnings Call Transcript ↗

August 04, 2025

Via The Motley Fool

Topics Earnings

If You'd Invested $1,000 in AbbVie (ABBV) Stock 10 Years Ago, Here's How Much You'd Have Today ↗

August 03, 2025

Via The Motley Fool

Expert Outlook: AbbVie Through The Eyes Of 4 Analysts ↗

August 01, 2025

Via Benzinga

Meta, Microsoft Power Wall Street To New Records Despite Inflation Jump: What's Moving Markets Thursday? ↗

July 31, 2025

A post-earnings surge in Meta Platforms Inc. (NASDAQ:META) and Microsoft Corp.

Via Benzinga

Topics Economy

AbbVie Raises 2025 Outlook After Q2 Beat ↗

August 04, 2025

Via The Motley Fool

Pfizer's Ascent Signals Broader Health Sector Resilience Amidst Innovation Wave

August 04, 2025

In a notable shift, shares of Pfizer (NYSE: PFE) have recently edged higher, reflecting a burgeoning strength within the broader health sector. This uptick signals a renewed investor confidence in the...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Nuclear Threats, Trump Fires Labor Statistics Chief, Fed Governor Resigns And More: This Week In Politics ↗

August 03, 2025

Via Benzinga

Topics Economy Government

Earnings Scheduled For July 31, 2025 ↗

July 31, 2025

Via Benzinga

3 Unstoppable Stocks to Buy in August ↗

August 02, 2025

Here are hot stocks to buy in a hot month.

Via The Motley Fool

Topics Intellectual Property

3 Dividend Champion Stocks I'm Watching in 2025 ↗

August 02, 2025

Other investors might want to watch these high-yield dividend stocks, too.

Via The Motley Fool

Topics Earnings Government World Trade

Why AbbVie Stock Flew Higher on Friday ↗

August 01, 2025

A solid quarterly earnings report reverberated though the pundit community that day.

Via The Motley Fool

Discover which S&P500 stocks are making waves on Friday. ↗

August 01, 2025

Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Friday as we examine the latest happenings in today's session.

Via Chartmill

AbbVie Soars On Skyrizi And Rinvoq Strength, Outpacing Humira Erosion ↗

August 01, 2025

AbbVie raised full-year guidance after Q2 sales beat expectations, with analysts lifting price targets despite an earnings miss.

Via Benzinga

Topics Earnings

Deal Dispatch: MEG Bidding War Heats Up, L Catterton Takes Bite Out Of Kisshokichi, Sunnova's Still Shining ↗

August 01, 2025

Big-name bidders, strategic reviews, and PE exits define an active, high-stakes M&A market so far this summer.

Via Benzinga

5 Dividend Stocks With Solid Returns And More Growth Ahead ↗

August 01, 2025

Via Benzinga

Why AbbVie (ABBV) Stock Is Up Today

August 01, 2025

Shares of pharmaceutical company AbbVie (NYSE:ABBV) jumped 3.7% in the afternoon session after the company posted strong second-quarter earnings that beat expectations and raised its full-year...

Via StockStory

3 Dividend Healthcare Stocks to Buy Hand Over Fist Before They Double ↗

August 01, 2025

These pharmaceutical giants are well worth a second look.

Via The Motley Fool

Trump Issues 60 Day Ultimatum To US Pharma Giants To Slash Drug Prices: 'If You Refuse To Step Up We Will...' ↗

August 01, 2025

President Donald Trump has issued a 60-day ultimatum to 17 major pharmaceutical companies, demanding that they lower drug prices in the U.S. or face severe consequences.

Via Benzinga

Topics Government

Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch ↗

July 31, 2025

Via Stocktwits

Topics Government

Why AbbVie Stock Slumped Today ↗

July 31, 2025

An encouraging quarterly earnings report was dampened by a new demand from President Trump.

Via The Motley Fool

Topics Government

AbbVie Stock Eyes Breakout as Pipeline and Profits Grow ↗

July 31, 2025

AbbVie stock pops after strong Q2 earnings and raised guidance, as Skyrizi and Rinvoq offset Humira's decline and support a bullish outlook

Via MarketBeat

AbbVie Lifts Outlook, Eyes Parkinson's Assets As Next Growth Frontier ↗

July 31, 2025

AbbVie posted $15.42 billion in Q2 revenue, topping estimates, with strong immunology and neuroscience growth, while full-year earnings guidance was raised.

Via Benzinga

AbbVie CEO Sees ‘Substantial Momentum’ For Remaining Year After Q2 Earnings Beat: Retail’s No Longer Pessimistic ↗

July 31, 2025

For the full year, the company raised its adjusted and diluted earnings per share guidance to $11.88 to $12.08, up from its previous guidance of $11.67 to $11.87.

Via Stocktwits

Topics Intellectual Property

AbbVie Inc (NYSE:ABBV) Beats Q2 2025 Earnings and Revenue Estimates, Raises Full-Year Guidance ↗

July 31, 2025

AbbVie beats Q2 2025 revenue and EPS estimates, raises full-year outlook. Stock surges 4.59% pre-market on strong portfolio performance and pipeline progress.

Via Chartmill

AbbVie’s (NYSE:ABBV) Q2: Beats On Revenue

July 31, 2025

Pharmaceutical company AbbVie (NYSE:ABBV) announced better-than-expected revenue in Q2 CY2025, with sales up 6.6% year on year to $15.42 billion. Its non-GAAP profit of $2.97 per share was 2.1% above...

Via StockStory

AbbVie Retail Traders Remain Wary Amid Report Of $1B Gilgamesh Deal To Boost Mental Health Pipeline ↗

July 30, 2025

The potential acquisition follows a 2023 licensing partnership between the two companies and comes after Gilgamesh reported promising trial results for its depression drug, GM-2505.

Via Stocktwits

Topics Intellectual Property

10 Health Care Stocks Whale Activity In Today's Session ↗

July 30, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

90 91 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

AbbVie (NY:ABBV)

All News about AbbVie

Starting at $3.75/week.

Subscribe Today